Mirion Technologies (MIR) Rises 8.4%: Could This Signal More Growth Ahead?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 19 2025
0mins
Should l Buy MIR?
Source: NASDAQ.COM
Mirion Technologies Stock Performance: Mirion Technologies, Inc. (MIR) shares rose 8.4% to $24.6, supported by strong trading volume and positive analyst ratings, with a 12.2% gain over the past month.
Earnings Expectations and Analyst Revisions: The company is expected to report quarterly earnings of $0.11 per share, a 37.5% increase year-over-year, but the consensus EPS estimate has been revised 9.1% lower recently, which may impact future stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIR
Wall Street analysts forecast MIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIR is 30.67 USD with a low forecast of 29.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.430
Low
29.00
Averages
30.67
High
34.00
Current: 25.430
Low
29.00
Averages
30.67
High
34.00
About MIR
Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target
- vTv Therapeutics Rating: Roth Capital analyst Adam Walsh initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $58, indicating significant upside potential from its current price of $33.54.
- MasTec Upgrade: Cantor Fitzgerald analyst Manish Somaiya initiated coverage on MasTec Inc (NYSE:MTZ) with an Overweight rating and a price target of $274, suggesting strong market optimism given its current price of $244.57.
- e.l.f. Beauty Analysis: Citigroup analyst Filippo Falorni initiated coverage on e.l.f. Beauty Inc (NYSE:ELF) with a Buy rating and a price target of $110, reflecting confidence in the brand's growth potential from its current price of $95.34.
- Decoy Therapeutics Outlook: Ladenburg Thalmann analyst Kevin DeGeeter initiated coverage on Decoy Therapeutics Inc (NASDAQ:DCOY) with a Buy rating and a price target of $2.5, indicating positive expectations for its market performance from its current price of $0.7505.
See More
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
- Significant Stock Surge: Shares of CG Oncology Inc soared 21.8% to $51.05 after the announcement of an expedited topline data readout for the PIVOT-006 clinical trial, reflecting strong market confidence in the company's future prospects.
- Clinical Trial Advancement: The trial compares adjuvant intravesical treatment versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer, and the earlier data release is expected to attract more investor interest, further propelling the company's growth.
- Positive Market Reaction: This stock price increase not only indicates investor optimism about CG Oncology's potential but may also enhance the company's financing capabilities in the biopharmaceutical sector, strengthening its competitive position.
- Significant Industry Impact: CG Oncology's progress could influence treatment standards for non-muscle invasive bladder cancer, prompting other companies in the industry to accelerate their R&D efforts, thereby boosting overall market vitality.
See More
MedMira Receives Health Canada Approval for Fast Syphilis Test
- Rapid Testing Milestone: MedMira received Health Canada approval for its Reveal®TP (Syphilis) rapid test in Q1 FY2026, making it the fastest syphilis antibody test approved in Canada, aimed at combating rising infectious disease rates.
- Clinical Trial Progress: The company has commenced the second phase of clinical trials for its Multiplo®Complete Syphilis Antibody Test, aiming to provide additional patient data for regulatory submission, with completion anticipated in Q1 2026.
- Financial Performance: In Q1 FY2026, the company reported revenues of $54,208, down from $61,723 in the same period last year, but net loss improved from $1,300,549 to $813,134, indicating a positive trend in loss reduction.
- Asset and Liability Changes: The company experienced a decrease in assets by $86,053 and an increase in liabilities by $727,081, leading to a higher working capital deficit of $2,502,278, reflecting financial pressure and the need for restructuring.
See More
Mirantis Joins Linux Foundation's AAIF as Silver Member to Accelerate AI Infrastructure Development
- Technical Collaboration: Mirantis officially joins the Linux Foundation's newly formed Agentic AI Foundation as a Silver Member, enabling participation in community events and working groups to drive rapid adoption and development of AI technology, thereby enhancing its influence in open-source AI projects.
- MCP Framework Launch: On September 30, Mirantis launched the MCP AdaptiveOps framework, providing engineering teams with a safe and reliable way to build and operate MCP servers, ensuring interoperability and compliance in a rapidly evolving ecosystem.
- Industry Leadership: Leveraging years of experience in highly regulated industries, Mirantis aids customers in transitioning to cloud-native IT infrastructure while supporting their AI workloads, further solidifying its leadership position in the enterprise AI sector.
- Client Base Expansion: Serving many of the world's leading enterprises, including Adobe and PayPal, Mirantis showcases its deep expertise in AI infrastructure technology, aiming to enhance customer value by streamlining operations and reducing time to market.
See More
Small Industrial Companies Poised for 'Supercycle': Ten Stocks to Capitalize On.
Definition of Supercycle: A supercycle refers to an extended period of strong economic growth that significantly boosts stock performance beyond typical cyclical upturns.
Impact on Stocks: Supercycles can lead to sustained increases in stock prices, driven by robust demand and favorable economic conditions.
Historical Context: Past supercycles have been influenced by major global trends, such as technological advancements and demographic shifts.
Current Outlook: Analysts are exploring whether current economic indicators suggest the onset of a new supercycle, which could reshape investment strategies.
See More
Industrials Poised for 'Supercycle': 10 Stocks to Capitalize On.
Definition of Supercycle: A supercycle refers to an extended period of strong economic growth that significantly boosts stock performance beyond typical cyclical upturns.
Impact on Stocks: Supercycles can lead to sustained increases in stock prices, driven by robust demand and favorable economic conditions.
Historical Context: Past supercycles have been influenced by major global events, such as technological advancements or significant infrastructure investments.
Current Outlook: Analysts are considering whether the current economic conditions may signal the onset of a new supercycle, which could benefit various sectors in the stock market.
See More
Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target
- vTv Therapeutics Rating: Roth Capital analyst Adam Walsh initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $58, indicating significant upside potential from its current price of $33.54.
- MasTec Upgrade: Cantor Fitzgerald analyst Manish Somaiya initiated coverage on MasTec Inc (NYSE:MTZ) with an Overweight rating and a price target of $274, suggesting strong market optimism given its current price of $244.57.
- e.l.f. Beauty Analysis: Citigroup analyst Filippo Falorni initiated coverage on e.l.f. Beauty Inc (NYSE:ELF) with a Buy rating and a price target of $110, reflecting confidence in the brand's growth potential from its current price of $95.34.
- Decoy Therapeutics Outlook: Ladenburg Thalmann analyst Kevin DeGeeter initiated coverage on Decoy Therapeutics Inc (NASDAQ:DCOY) with a Buy rating and a price target of $2.5, indicating positive expectations for its market performance from its current price of $0.7505.
See More
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
- Significant Stock Surge: Shares of CG Oncology Inc soared 21.8% to $51.05 after the announcement of an expedited topline data readout for the PIVOT-006 clinical trial, reflecting strong market confidence in the company's future prospects.
- Clinical Trial Advancement: The trial compares adjuvant intravesical treatment versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer, and the earlier data release is expected to attract more investor interest, further propelling the company's growth.
- Positive Market Reaction: This stock price increase not only indicates investor optimism about CG Oncology's potential but may also enhance the company's financing capabilities in the biopharmaceutical sector, strengthening its competitive position.
- Significant Industry Impact: CG Oncology's progress could influence treatment standards for non-muscle invasive bladder cancer, prompting other companies in the industry to accelerate their R&D efforts, thereby boosting overall market vitality.
See More
MedMira Receives Health Canada Approval for Fast Syphilis Test
- Rapid Testing Milestone: MedMira received Health Canada approval for its Reveal®TP (Syphilis) rapid test in Q1 FY2026, making it the fastest syphilis antibody test approved in Canada, aimed at combating rising infectious disease rates.
- Clinical Trial Progress: The company has commenced the second phase of clinical trials for its Multiplo®Complete Syphilis Antibody Test, aiming to provide additional patient data for regulatory submission, with completion anticipated in Q1 2026.
- Financial Performance: In Q1 FY2026, the company reported revenues of $54,208, down from $61,723 in the same period last year, but net loss improved from $1,300,549 to $813,134, indicating a positive trend in loss reduction.
- Asset and Liability Changes: The company experienced a decrease in assets by $86,053 and an increase in liabilities by $727,081, leading to a higher working capital deficit of $2,502,278, reflecting financial pressure and the need for restructuring.
See More
Mirantis Joins Linux Foundation's AAIF as Silver Member to Accelerate AI Infrastructure Development
- Technical Collaboration: Mirantis officially joins the Linux Foundation's newly formed Agentic AI Foundation as a Silver Member, enabling participation in community events and working groups to drive rapid adoption and development of AI technology, thereby enhancing its influence in open-source AI projects.
- MCP Framework Launch: On September 30, Mirantis launched the MCP AdaptiveOps framework, providing engineering teams with a safe and reliable way to build and operate MCP servers, ensuring interoperability and compliance in a rapidly evolving ecosystem.
- Industry Leadership: Leveraging years of experience in highly regulated industries, Mirantis aids customers in transitioning to cloud-native IT infrastructure while supporting their AI workloads, further solidifying its leadership position in the enterprise AI sector.
- Client Base Expansion: Serving many of the world's leading enterprises, including Adobe and PayPal, Mirantis showcases its deep expertise in AI infrastructure technology, aiming to enhance customer value by streamlining operations and reducing time to market.
See More
Small Industrial Companies Poised for 'Supercycle': Ten Stocks to Capitalize On.
Definition of Supercycle: A supercycle refers to an extended period of strong economic growth that significantly boosts stock performance beyond typical cyclical upturns.
Impact on Stocks: Supercycles can lead to sustained increases in stock prices, driven by robust demand and favorable economic conditions.
Historical Context: Past supercycles have been influenced by major global trends, such as technological advancements and demographic shifts.
Current Outlook: Analysts are exploring whether current economic indicators suggest the onset of a new supercycle, which could reshape investment strategies.
See More
Industrials Poised for 'Supercycle': 10 Stocks to Capitalize On.
Definition of Supercycle: A supercycle refers to an extended period of strong economic growth that significantly boosts stock performance beyond typical cyclical upturns.
Impact on Stocks: Supercycles can lead to sustained increases in stock prices, driven by robust demand and favorable economic conditions.
Historical Context: Past supercycles have been influenced by major global events, such as technological advancements or significant infrastructure investments.
Current Outlook: Analysts are considering whether the current economic conditions may signal the onset of a new supercycle, which could benefit various sectors in the stock market.
See More
